Trial Profile

A prospective open label study to determine safety and efficacy of Glecaprevir/Pibrentasvir plus ezetimibe for eight days in non-liver solid organ transplant recipients in preventing chronic HCV infection

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Dec 2022 New trial record
08 Nov 2022 According to results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases, this study continues to enroll and the final that data will be presented at the meeting.
08 Nov 2022 Results (n=71) presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com